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Strategies that can reduce harmful side effects of potent immunomodulatory drugs are in 
high demand to facilitate clinical translation of the newest generation of immunotherapy. 
Indeed, uncontrolled triggering of the immune system can lead to life-threatening cascade 
reactions such as e.g. cytokine storm. In particular, drug formulations that combine 
simplicity and degradability are of formidable relevance. Imidazoquinolines are an 
excellent example of such small molecule immunomodulatory drugs that exhibit in 
unformulated form a highly undesirable pharmacokinetic profile. Imidazoquinolines are 
potent inducers of type I interferons that are of great interest in the context of anti-cancer 
and anti-viral therapy through triggering of Toll like receptors 7 and 8. In this paper we 
aimed to alter the pharmacokinetic profile of imidazoquinolines using a simple, yet 
efficient, strategy that holds high potential for clinical translation. Hereto, we conjugated 
an imidazoquinoline to the backbone of poly(aspartate) and further formulated this into a 
degradable coacervate through complex coacervation with a non-toxic degradable 
polycation. The intrinsic TLR activity of the imidazoquinoline was well preserved and our 
formulation strategy offered spatial control over its biological activity in vivo 
INTRODUCTION 
Small molecule drugs that can provoke innate immune activation through triggering of 
specific receptors expressed by innate immune cell subsets are of great relevance for 
cancer immunotherapy and vaccine development.1 However, the major obstacles for 
clinical translation of many of these molecules are their poor physicochemical and 
pharmacokinetic properties in vivo affording dose-limiting toxicities. Hence, strategies that 
can reduce unwanted side effects of potent immunomodulatory drugs are in high demand 
to facilitate clinical translation of the newest generation of immunotherapeutics. Indeed, 
uncontrolled triggering of the immune system can lead to life-threatening cascade 
reactions such as cytokine storm.2 Additionally, non-degradable by-products from 
specifically designed drug delivery systems can be prone to long-term accumulation. 
Therefore, drug formulations that combine simplicity and degradability are of great 
relevance.3, 4  
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Toll like receptors (TLRs) are a class of natural immune pattern recognition receptors, 
which can mediate both natural and adaptive immunity in humans and rodents.5-7 Most 
TLRs can activate the host defense system, produce IL-1 β, IL-6, TNF-α, and chemotactic 
cytokines, thereby regulating the Th1/Th2 balance.8 In recent years, TLR agonists have 
attracted much attention as adjuvants or immunomodulators for tumor immunotherapy.9, 
10 Single stranded viral RNA is the natural ligand of TLR7/8 and is a potent trigger of anti-
viral and anti-tumoral responses.11 Interestingly, a wide range of potent small molecule 
agonists of TLR7/8 have been discovered but are an exquisite example of 
immunomodulatory drugs that in unformulated state rapidly distribute throughout the 
whole body and cause systemic inflammation. TLR7/8 are localized on the endosomal 
membrane of innate immune cells which are therapeutic targets to promote antigen 
presentation and mount tumor-specific adaptive immunity.12 Previously, we and others 
have demonstrated that covalent conjugation of imidazoquinolines to macromolecular or 
colloidal carriers strongly abrogates systemic dissemination but rather confers the type I 
interferon response to the site of administration and to draining lymphoid tissue.13-17 The 
latter is of particular interest in the context of using these systems for localized cancer 
immunotherapy or as a vaccine adjuvant. Immune cells located in specific areas of 
lymphoid tissue not only respond to antigens from distal infection, but also receive antigen 
from antigen presenting cells that are recruited from nearby tumor or a site of infection.  
In this paper we aimed to alter the unwanted pharmacokinetic profile of 
imidazoquinolines using a simple, yet efficient, strategy that holds high potential for 
clinical translation. Hereto we conjugated an imidazoquinoline to the backbone of the 
biodegradable polypeptide poly(L-aspartic acid) at its primary amine position to offer 
spatial controlling, and further formulated this conjugation into a degradable coacervate 
through complex coacervation with a non-toxic degradable polycation to circumvent 
systemic immune-stimulation. Importantly, no multi-step reaction or toxic 
solvents/reagents were required during formulation which makes it safe and 
biocompatible. The intrinsic TLR activity of the imidazoquinoline could be well preserved 
and its biological activity in vivo spatially confined to the local site of administration. 
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RESULTS AND DISCUSSION 
Synthesis and characterization 
Polyaspartic acid (PASP) is a biodegradable polypeptide, that was synthesized from 
polysuccinimide (PSI) as a precursor polymer (Scheme 1). In a first step, polysuccinimide 
(PSI) was synthesized by acid-catalysed polycondensation of aspartic acid,18, 19 resulting 
in a polymer with a number average molar mass of 6.2KDa and a dispersity (Đ) of 1.49 
(according to SEC in DMAc), with only 3% of branched polymer formed (according to 1H-
NMR) (Figure S1-3). In a subsequent step, the resulting PSI was treated with aqueous 
sodium hydroxide, which induces opening of the succinimide ring. After purification via 
dialysis against demi water, successful synthesis of PASP was evidenced by 1H-NMR 
spectroscopy, containing 75% of beta form and 25% of alpha form along the polymer 
chain (according to 1H-NMR) (Figure S4, S5). Contrary to solid phase synthesis or ring-
opening polymerization of N-carboxyanhydride monomers, this route excels in simplicity 
and does neither require the use of multiple reaction and deprotection cycles (applied in 
solid phase synthesis) nor hazardous chemicals or carefully monitored reaction 
conditions (as for NCA polymerization). The resulting polypeptide is equipped with a 
relatively moderate dispersity, thus, making it also highly attractive for large scale 
industrial production and applications. 
Next, the TLR7/8 agonist IMDQ was covalently conjugated to the polymer through 
amide bond formation between the primary amine of the IMDQ and carboxylic acid 
moieties on the PASP backbone using DMTMM to facilitate amide bond formation.20 
When needed for further fluorescence-based assays, fluorescently labelled PASP-IMDQ 
was prepared by conjugating an amine-bearing fluorescent dye to the PASP backbone in 
a similar fashion as for IMDQ. Finally, after purification by dialysis, PASP-IMDQ could be 
isolated in dry form by lyophilization. The absence of free IMDQ was confirmed by HPLC 
analysis (Figure S6) and the amount of IMDQ in PASP-IMDQ was calculated based on 
UV-Vis spectroscopy to be 15% (w/w) (Figure S7). 
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Scheme 1. Synthesis of poly(aspartate) (PASP) and conjugation of the TLR7/8 agonist IMDQ. (A) 
polysuccinimide (PSI) was synthesized by acid-catalysed polycondensation of L-aspartic acid. (B) PSI was 
treated with NaOH, which yields opening of the succinimide rings. (C) the TLR7/8 agonist IMDQ was 
covalently conjugated to the polymer through amide bond formation between primary amino group of the 
IMDQ and carboxylic acid group of the PASP facilitated by DMTMM.  
In vitro cell uptake and innate immune activation 
First, the cytotoxicity of the polymer was evaluated by MTT assay, revealing PASP-
IMDQ to be non-toxic up to a concentration of 13 μM (i.e. >100 μg/mL) (Figure 1A). Next, 
we examined the in vitro uptake of the polymer by mouse RAW macrophages as model 
innate immune cells. Because TLR7/8 is localized on the endosomal membrane, PASP-
IMDQ must be endocytosed by the cells in order for IMDQ to reach its target receptor.12 
RAW macrophages were pulsed with rhoPASP-IMDQ (i.e. bearing a rhodamine label) 
followed by flow cytometry (FACS) analysis and confocal microscopy imaging. FACS 
analysis revealed that rhoPASP-IMDQ associated to cells in a dose-dependent manner 
(Figure 1B). Confocal microscopy confirmed that the polymer was indeed internalized by 
the macrophages, the punctuated fluorescence pattern hinting at accumulation in 
endolysosomal vesicles (Figure 1C), which is in line with our earlier findings with regard 
to subcellular localization of macromolecular IMDQ conjugates. 14 
Next, we set out to determine whether PASP-IMDQ can trigger TLR activation. Hereto 















































determination of TLR agonistic activity by simple spectrophotometric detection of SEAP 
enzymatic activity. As shown in Figure 1D, control PASP (i.e. without IMDQ) did not 
induce activation, suggesting that the polymer on its own is poorly immunogenic, at least 
under the experimental conditions. By contrast, PASP-IMDQ strongly promoted TLR-
activation at an almost equal potency as IMDQ in soluble form. These findings are 
interesting as in our previous work on macromolecular IMDQ-conjugates, typically a 2-3 
log loss in activity was observed when IMDQ was conjugated to a carrier, relative to IMDQ 
in soluble form, likely due to sterical hindrance caused by the macromolecular carrier. We 
hypothesize that the polypeptide backbone could be prone to degradation by endosomal 
peptidases upon cellular uptake, which would result in smaller fragments that pose less 
sterical hindrance to IMDQ for reaching the target binding pocket.  
 
Figure 1. In vitro cellular uptake and innate immune activation of PASP-IMDQ. (A) Cytotoxicity (assessed 
by MTT assay) on RAW Blue macrophage pulsed with native soluble IMDQ, PASP, PEAD and PASP-IMDQ, 
as well as coacervated PEAD/PASP and PEAD/PASP-IMDQ (n=6). (B) Flow cytometry analysis of RAW 
Blue macrophage pulsed with rhoPASP-IMDQ (i.e. bearing a rhodamine label) and coacervated PEAD/ 
rhoPASP-IMDQ (n=3). (C) Corresponding confocal microscopy image of RAW Blue macrophage pulsed 
with rhoPASP-IMDQ. Scale bar represents 15 micron. (D) RAW Blue pan TLR-reporter cell assay (by 
spectrophotometric detection of SEAP enzymatic activity) measuring TLR agonistic activity of native soluble 
IMDQ, PASP, PEAD and PASP-IMDQ, as well as coacervated PEAD/PASP and PEAD/PASP-IMDQ (n=6). 
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Complex coacervation 
To allow for a more prolonged stimulation in the tumor microenvironment we reasoned 
that complex (electrostatic) coacervation of PASP-IMDQ with a degradable cationic 
polymer could be a viable option. Poly(ethylene argininylaspartate diglyceride) (PEAD), 
is a non-toxic biodegradable polycation with high biocompatibility and which has 
previously been shown to exhibit high affinity towards biological polyanions such as DNA, 
heparin and hyaluronic acid, forming complex coacervate droplets.21, 22 
At first we attempted to derive the optimal conditions for complex coacervation of PASP-
IMDQ and PEAD. Testing several concentration and ratios of both compounds resulted 
in selecting a 5:1 (w/w) ratio of PEAD to PASP-IMDQ at a PEAD concentration of 25 
mg/mL and a PASP-IMDQ concentration of 5 mg/mL as to be optimal in terms of PASP-
IMDQ encapsulation (i.e. 90%) while limiting the excess of free PEAD (Figure S8). Figure 
2A shows a confocal microscopy image of the PEAD/ rhoPASP-IMDQ system which 
clearly shows the presence of coacervate droplets with a size between 1-20 micron. To 
measure the release of PASP from the coacervate we incubate the PEAD/rhoPASP-
IMDQ in phosphate buffered saline (PBS) at pH 7.4 and 37℃, followed by sample 
collection, centrifugation and determination of the amount of rhoPASP in the supernatant. 
As shown in Figure 2B, a sustained release for up to 12h in vitro is achieved by 
coacervation of PASP with PEAD. However, it is important to note that in this experiment 
the coacervate was suspended in aqueous medium, whereas upon injection in tissue the 
excess of water will diffuse and the coacervate will form a tightly packed gel which we 
hypothesize will presumably exhibit significantly slower PASP-IMDQ release kinetics. 
Flow cytometry analysis showed no difercence in cellular asosciatiom between rhoPASP-
IMDQ and PEAD/rhoPASP-IMDQ (Figure 1B), which we attribute to rhoPASP-IMDQ 
being readily released from the coacervate droplets under the diluted conditions used for 
in vitro experiments. Similar findings were observed when assessing the TLR agonistic 
acitivy of PEAD/rhoPASP-IMDQ (Figure 1D), proving that coacervate-formulated IMDQ 




Figure 2. Characteristics of PEAD/PASP-IMDQ system.  (A) A confocal microscopy image of the PEAD/ 
rhoPASP-IMDQ coacervate. Scale bar represents 20 micron. (B) Release of Cy5.5PASP from the 
coacervate PEAD/ Cy5.5PASP in phosphate buffered saline at pH 7.4 and 37℃. 
 
In vivo innate immune activation  
To assess to what extent our formulation strategy influences the spatial distribution of 
innate immune activation by PASP-IMDQ we made use of an IFN-β luciferase (IFNβ+/Δβ-
luc) reporter mouse model. In this model, a firefly luciferase reporter gene is linked to the 
type I interferon, IFN-β.23 Mice were injected intradermally in the flank with an equivalent 
dose of 10μg of IMDQ in soluble and in PEAD/PASP-IMDQ form, followed by non-
invasive full body luminescence imaging. As depicted in Figure 3A, a strong systemic 
IFN-β response was induced by soluble IMDQ with a profound expression of IFN-β in a 
variety of major organs, which is likely due to rapid diffusion of IMDQ from injected site 
into the circulation. By contrast, PEAD/PASP-IMDQ induced a strongly localized 
immunomodulatory response. We then calculated the ratio of local to the total 
luminescence, which pointed out the ability of PEAD/PASP-IMDQ to supress systemic 
inflammatory responses and rather restrict its biological activation at the site of 
administration (Figure 3B).  
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Figure 3. (A) In vivo luminescence images of IFNβ-luciferase reporter mice that received intradermal 
injection in the flank with 10 μg of IMDQ and PEAD/PASP-IMDQ (empty PEAD/PASP was included as 
control). (B) Quantification of the luminescence data. (n=3; Student t-test on AUC: *: p<0.05) 
Anti-tumoral activity 
Recent preclinical and clinical studies indicate that intratumoral administration of TLR 
agonists stimulates antigen-presenting cells and helps reverse the immunosuppressive 
microenvironment that protects large established tumors from immune elimination. The 
activation of antigen-presenting cells (such as dendritic cells (DCs)) results in the 
production of proinflammatory cytokines, and supports antigen presentation to CD8 T 
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cells in lymphoid tissue thereby promoting anti-tumor immunity.24 As a monotherapy, the 
administration of TLR7/8 agonists conjugates or loaded nanoparticles leads to controlled 
tumor growth.9, 23 Encouraged by these findings, we engaged into assessing the 
therapeutic potential of PASP-IMDQ in a cancer immunotherapy context. For this purpose, 
we made use of the murine CT26 colon carcinoma model, which is characterized by a 
highly immunogenic tumor microenvironemt, expressing numerous neo-antigens, and 
which has become a popular platform model for evaluating therapeutic stretgaies 
involving innate and adaptive immune activation.  
To test the anti-tumor efficacy of PEAD/ PASP-IMDQ, CT26 mouse colon cancer 
tumors were grown in BALB/C mice and when a volume of around 100mm3 was reached, 
mice were treated by intratumoral injection. Figure 4 depicts the effect of treatment on 
tumor growth as a function of time. When given repeatedly in native form from or in PASP-
IMDQ conjugated form, IMDQ only induced a minor decrease in tumor growth. However, 
mice treated with PEAD-PASP-IMDQ coacervate showed a significant decrease in tumor 
growth. Eralier, we have demonstrated in a B16 mouse melanoma model that innate 
immune activation in the tunor microenvironment by intratuoral administration of IMDQ 
induces activation of DCs in sentinel lymph nodes and presentation of tumor antigen to T 
cells, thereby inducing robust proliferation of antigen-specific CD9 T cells.  In the context 
of the present study, our data strongly point at linking the ability of PEAD/ PASP-IMDQ to 
induce prolongued innate immune stimulation in the tumor microenvironment (cfr. Figure 
3) to the induction of anti-tumor adaptive immunity. In parallel, we monitored the body 
weight of the animals (Figure S9) which was found to remain stable over the duration of 
the experiment, thereby suggesting that the treatment was fairly well tolerated.  
 11 
 
Figure 4. Therapeutic effect on tumour growth as a function of time. CT-26 mouse colon cancer tumours 
were grown in BALB/C mice and when a volume of 100 mm3 was reached, mice were treated by 
intratumoral injection of 50μL of IMDQ, PASP-IMDQ and PEAD/ PASP-IMDQ. (n=6: Student t-test on AUC: 
*: p<0.05) 
CONCLUSIONS 
In conclusion, we have shown in this work that conjugation of IMDQ, a highly potent 
immune-modulatory drug, to poly(aspartate) (i.e. PASP-IMDQ) is a highly attractive 
strategy to on the one hand preserve the intrinsic TLR agonistic activity of IMDQ, while 
strongly restricting the biological activity in vivo to the local site of administration. When 
formulating PASP-IMDQ into a coacervate through complex coacervation with PEAD, a 
non-toxic degradable polycation, a potent anti-tumoral effect is observed, attributed to 
prolongued innate immune stimulation in the tumor microenvironemt. Our findings 
highlight PEAD/ PASP-IMDQ as a safe type of immunotherapy with – owing to its 
chemical simplicity and easy preparation – high translational potential. 
MATERIALS AND METHODS 
Materials. Unless otherwise stated, all chemicals were purchased from Sigma Aldrich. 
Tetramethylrhodamine(TMR) cadaverine was obtained from Life Technologies. The 
TLR7/8 agonist IMDQ (1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-
amine) was synthesized as earlier reported.25 Dialysis was performed using Spectra/Por 
3 membranes obtained from Spectrum Labs. The RAW Blue cell line and Quanti blue 
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stain was obtained from Invivogen. Cell culture medium and supplements, Hoechst, and 
Zeocin were purchased from Invitrogen.  
Cells were cultured in RPMI Medium 1640 supplemented with 10% heat-inactivated 
fetal bovine serum, 1% penicillin/streptomycin, 2 ×10-3 M L-glutamine, 1 ×10-3 M sodium 
pyruvate and 0.01% Zeocin and incubated at 37 ℃ with 5% CO2 saturation. Mouse 
experiments were conducted following the European guidelines for animal experiments 
and approved by the local ethical committee for animal experiments of Ghent University 
(EC2018/92). Female BALB/c mice (weight: 18–22 g), in the range of 6-8weeks, were 
supplied by the Medical Animal Test Center of Shandong University (Jinan, China). The 
animals were fed with a standard diet and allowed water ad libitum. All experiments were 
carried out in compliance with the Animal Management Rules of the Ministry of Health of 
the People's Republic of China (document number 55, 2001) and the Animal Experiment 
Ethics Review of Shandong University. 
Synthesis of poly-L-aspartic acid. To prepare the polysuccinimide precursor polymer, 
first L-aspartic acid (25g, 0.188mol) and phosphoric acid (1.862g, 0.019mol) was 
dissolved in 56 mL mesitylene and 24 mL DMF in a round-bottom flask and refluxed for 
24h under nitrogen atmosphere. Next, the solvent was removed by evaporating at 
reduced pressure and the residue was dissolved in DMF followed by precipitation in water. 
The precipitate was washed with water several times until neutral. The final product was 
dried under vacuum at 80°C for 24h.  
To hydrolyze the succinimide motifs, PSI was added to an aqueous solution of NaOH 
(0.2M) while stirring at room temperature for 24 h. The pH of the resulting solution was 
neutralized by addition of an aqueous HCl solution (0.1M), followed by dialyzed against 
demi water (MWCO 3.5KDa). The sodium salt of poly(aspartic acid) was isolated in dry 
form by freeze-drying. 
1H-NMR spectra were recorded on a Bruker 300MHz or 400MHz FT NMR spectrometer. 
Chemical shifts(δ) are provided in ppm relative to TMS.  
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Molecular weight and dispersity of the precursor polymer PSI was measured by size 
exclusion chromatography (SEC) using dimethylacetamide(DMAc) containing 50 mM 
LiBr as eluent. The SEC system consisted of a 20A ISO-pump, a 20A refractive index 
detector (RID) and an AS 1555 auto sampler. Measurements were recorded at 50℃ with 
a flow rate of 0.7 mL/min. Calibration of the 2 PL 5μm Mixed-D columns was done with 
poly(methyl methacrylate) (PMMA) standards obtained from PSS (Mainz, Germany). 
Conjugation of IMDQ to poly-L-aspartic acid (PASP-IMDQ). PASP-IMDQ was 
synthesized through amide bond formation between carboxylic acid motifs on the PASP 
backbone and the aliphatic amine of IMDQ. Briefly, to a 10mg/mL solution of PASP in a 
phosphate saline buffer (PBS) (10mL), 1.5 molar excess of DMTMM in relation to IMDQ 
was added followed by 10mg of IMDQ dissolved in DMSO (10mg/mL) under continuous 
stirring. After reaction for three days at room temperature, the solution was transferred 
into a dialysis membrane (MWCO: 3.5KDa) and dialyzed against 0.1M NaCl for three 
days. Subsequent dialysis against demi water for 8h and lyophilization afforded PASP-
IMDQ as a dry powder.  
In case of fluorescent labelling, 50μL of amine-containing fluorescent dye (10mg/mL in 
DMSO) was added after addition of the IMDQ in the above-described synthesis protocol.  
To confirm successful conjugation of IMDQ to the PASP backbone and to confirm 
removal of freely soluble IMDQ by the dialysis step, high-performance liquid 
chromatography (HPLC) analysis was performed using a Merck, Hitachi LaChrom HPLC 
system equipped with an isocratic solvent pump (L-7100) set at a flow rate of 1mL/min, 
an autosampler (L-7200) with a loop of 100microL, a guard column (RP 18e) followed by 
a reversed phase C18 column (LiChroCart® 250-4, LiChrospher® 100 RP (5μm)) and a 
UV-detector (L-7400) set at a wavelength of 250nm. The mobile phase consisted of 
65%water-35%acetonitrile (supplemented with 0.1% (V/V) trifluoroacetic acid) and the 
injection volume was set at 10μL.  
The amount of TLR7/8 agonist IMDQ attached to the polymer was determined by UV-
Vis spectroscopy. Briefly, samples were dissolved in PBS at known concentrations and 
added to quartz cuvettes with a path length of 1cm. UV-Vis spectra were recorded on a 
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Shimadzu UV-1650PC spectrophotometer over a spectrum from 250-450nm. The 
amount of IMDQ was calculated based on the obtained calibration curve of IMDQ as a 
function of concentration. 
Coacervate formation. PEAD was synthesized as previously described by the Wang's 
lab.26 Briefly, PEAD was synthesized by polycondensation of aspartic acid and ethylene 
glycol diglycidyl ether (EGDE), followed by the conjugation of arginine which provided 
positive charges to the polymer. 
Under physiological conditions, PEAD has two cationic groups (amine and guanidine) 
per repeating unit, and should interact strongly with negatively charged macromolecules 
through coulombic attraction. Upon addition of PEAD to PASP solution, the solution 
became turbid and the highest turbidity was reached with a PEAD to PASP mass ratio of 
5:1, indicating that the PEAD/PASP complex is likely neutral at this ratio. PEAD was 
dissolved at 25mg/mL in demi water and mixed with PASP at a concentration of 5mg/mL.  
In vitro experiments. 
Flow cytometry. RAW mouse macrophages were seeded in a 24-well plate at a density 
of 250,000 cells mL-1 one day before the cells were pulsed with rhoPASP-IMDQ and 
PEAD/ rhoPASP-IMDQ coacervate at different concentrations. After 24h of incubation, 
the macrophages were dissociated using cell dissociation buffer followed by 
centrifugation for 5min at 200G. Flow cytometry analysis was performed on a BD Accuri. 
Data were processed using the FlowJo software package. 
Confocal microscopy. RAW mouse macrophages were seeded in a glass bottom Will-
co dish at a density of 250,000 cell mL-1 and incubated overnight before the cells were 
pulsed with rhoPASP-IMDQ. After 24h incubation, cells were fixated in a 4% 
paraformaldehyde solution for 30min at 37℃ and subsequently washed and 
simultaneously stained by Hoechst for 1h at room temperature. Finally, the samples were 
washed with PBS and imaged by a confocal microscope (Leica DMI6000 B inverted 241 
microscope) equipped with an oil immersion objective (Zeiss, 63×, NA 1.40) and attached 
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to an Andor DSD2 confocal scanner. Images were processed using the ImageJ software 
package. 
In vitro RAW Blue assay. RAW Blue macrophages were seeded in a 96-well round 
bottom plate with 180μL of cells suspension in each well at a density of 50,000 cells mL-
1 and immediately pulsed with 20μL of test compounds at desired concentrations in six-
fold. As a negative control, PBS was added. After 24h incubation, 50μL of the supernatant 
was transferred into a 96-well flat bottom plate and incubated with 150μL of Quanti blue 
solution. After 0.5 to 2h incubation at 37℃, the color change absorbance was measured 
with a plate reader at 620-655nm. 
MTT assay. Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. RAW mouse macrophages were seeded in a 
96-well plate with 100μL of cells suspension in each well at a density of 50,000 cells mL-
1 and immediately pulsed with native soluble IMDQ, PASP, PEAD and PASP-IMDQ, as 
well as coacervated PEAD/PASP and PEAD/PASP-IMDQ at desired concentrations in 
six-fold. After 24h incubation, 40μL of the MTT reagent (1mg/mL) was added to the 
samples. The formed formazan crystals after an incubation period of 2-3h were dissolved 
in 100 μL of a 10% m/v SDS/0.01M HCl solution overnight protected from light. The 
absorbance was measured by a microplate reader at 570nm. As a negative and positive 
control, PBS and DMSO were added to the wells, respectively. 
In vivo innate immune activation. Heterozygous IFN-reporter mice (BALB/c-
Ifnb1tm1.2Lien) in the range of 7-9 weeks were housed in individual ventilated cages and 
given ad libitum access to food and water. The mice were subjected to treatment with 
intradermal injection in the flank with a dose of 10μg (in 20 μL of PBS) of PASP, PASP-
IMDQ, or IMDQ (n=3). For in vivo imaging, mice were injected subcutaneously with 200 
μl D-luciferin (15 mg/ml, Gold Biotechnology, USA) at the given time points (4, 24, and 
48h post injection), and in vivo luminescence imaging was recorded 12 min later using 
the IVIS Lumina II imaging system (PerkinElmer, USA). Local (flank) and full-body 
luminescence were quantified using the Living Image 4.4 software (Caliper life sciences, 
Hopkinton, MA). 
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In vivo therapeutic anti-tumor response. CT-26 bearing female BALB/c mice were 
used to investigate the in vivo therapeutic anti-tumor response. In total, 5×105 CT- 26 
cells suspended in 100 μl of demi water were injected s.c. into the left flank of each 
BALB/c mice, respectively. After inoculation of the tumor cells, the solid tumors were 
allowed to grow ≥100 mm3, then mice were divided into four  groups (six mice per group): 
(1) demi water (Control); (2) IMDQ (0.2mg/mL); (3) PASP-IMDQ (2mg/mL); (4) 
PEAD/PASP-IMDQ suspension.   
The mice in each group were treated with the above formulations by intratumoral 
injection every 3 days. After the first administration, the tumors diameters were measured 
with calipers and the body weights of the mice were measured using an electronic balance 
every 3 days. The tumor volume was calculated using the following Eq.: 
V= (a*b2)/2 
where a and b represent the length and width of the tumor, respectively. The mice were 
humanely euthanized when the volume of the tumor reached 10000mm3. 
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